Seoul, South Korea

Hyun-Ju Sung


Average Co-Inventor Count = 5.9

ph-index = 4

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 2009-2016

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Innovations of Hyun-Ju Sung in Anticancer Prodrugs

Introduction

Hyun-Ju Sung is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of medicinal chemistry, particularly in the development of anticancer prodrugs. With a total of 7 patents to his name, his work focuses on enhancing the efficacy and safety of cancer treatments.

Latest Patents

One of his latest patents is titled "Anticancer prodrug activated by radiation or ultraviolet treatment and use thereof." This invention relates to an anticancer prodrug that consists of a peptide linked to an anticancer drug, such as doxorubicin, which is known to be unstable in acidic or basic environments. The prodrug remains in a non-toxic inactive form when administered into the body. However, it effectively releases the active anticancer drug in the target area when activated by caspase through radiation or UV treatment. This innovative approach maximizes the therapeutic effects on cancer cells while minimizing the side effects typically associated with chemotherapy.

Career Highlights

Hyun-Ju Sung has worked with notable organizations, including Samsung Electronics Co., Ltd. and the Korea Institute of Science and Technology. His experience in these institutions has contributed to his expertise in developing advanced therapeutic solutions.

Collaborations

He has collaborated with several professionals in his field, including Se-Myeong Jang and Makoto Yoshida. These collaborations have further enriched his research and development efforts.

Conclusion

Hyun-Ju Sung's innovative work in the field of anticancer prodrugs demonstrates his commitment to improving cancer treatment methodologies. His patents reflect a significant advancement in the therapeutic landscape, aiming to provide more effective and safer options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…